Since mutagens produce an extraordinary diversity of mutational patterns, differential mutational exposures among populations are expected to produce different patterns of mutation. Classical epidemiological methods have been successful in implicating specific mutagens in cancers such as those of lung and skin in which one mutagen predominates. In breast cancer, however, no mutagens have been implicated in an unequivocal manner.
Introduction
The pattern of acquired mutations in identical regions of a given gene in the same cancer type offers the possibility of detecting differences in mutagenic processes in different populations (1, 2, 3) . The mutational pattern in the p53 gene is a particularly useful epidemiological tool for exploring mechanisms of mutagenesis because this gene is altered frequently in nearly all types of human cancers (reviewed in reference 4). Differences in (5) ; G-OT transversions in codon 249, aflatoxin B, exposure and hepatocellular carcinoma (6, 7) ; and CC-'TT tandem dipyrimidine transitions, UV-B radiation, and squamous and basal cell carcinomas of the skin (8, 9) .
We are studying patterns of p53 gene mutation in breast cancers of populations at different risk for this disease to look for evidence that different environmental or endogenous factors contribute to mammary carcinogenesis to different extents (10, 11) . In breast cancer the frequency of the disease varies more then fivefold between low-risk groups like Japanese women and high-risk populations like Caucasian women living in North America or Europe (12, 13) . Immigration from a low-risk region (Japan) to a high risk region (California) substantially increases the frequency of disease (14) (15) (16) , but no mutagens have been implicated in an unequivocal manner. We have shown that the pattern of p53 mutations in white, largely rural Midwestern U.S. women (11, 17) differs from the pattern in inner city African American women in Detroit, Michigan (18) and that reported in Scottish women (19 Amplification and sequencing. Clusters of 50-100 tumor cells from touch preparations of the surface of partially thawed breast cancer tissue were used for the molecular analysis as described previously (10) . Genomic amplification with transcript sequencing (GAWTS) was performed according to Stoflet et al. (20) . PCR and sequencing primers for exons 5-9 and adjacent intronic regions were as described previously (10, 11) . Immunohistochemistry. Clusters of tumors cells in touch preparations were stained for expression of p53 as described previously (10, 11) . Briefly (22) , and compared between women with a mutation versus women without a mutation by the exact logrank statistic (23) . To adjust for the prognostic factors, ER, PR, and lymph node status, we performed a stratified log-rank statistic, stratifying on the prognostic factor.
Results
14 mutations (23.3%) were found in exons 5-9 and adjacent intronic regions among the 60 Austrian breast cancers studied (Table I ). This frequency of mutation is similar to the frequencies of p53 mutation in breast cancers of other European women (Table H) . Only neoplastic cells were analyzed for mutations in the p53 gene. However, the vast majority of the detected mutations are presumed to be of somatic origin, because germline mutations in the p53 gene in women with breast cancer are rare even in a sample enriched for women with onset of the disease before age 35 or with a family history of breast cancer (24).
The three tumors with nonsense mutations or frameshift alterations did not express p53, whereas the only tumor with a splice site mutation (345T) did show nuclear immunoreactivity with all three antibodies (see Table I , asterisk). Of the 10 breast cancers with missense mutations, all but one expressed p53, detectable with at least two of the three antibodies used (Table  I) . The exception was a tumor with a G:C-+A:T transition in codon 246 (tumor 347T) changing a methionine to isoleucine. For analysis of the mutational pattern, the mutations were classified into eight groups: deletions/insertions, G:C--A:T transitions at the dinucleotide CpG, G:C-+A:T transitions not at CpG, A:T-{G:C transitions, and the four types of transversions. No statistically significant strand bias was observed, although 5 of 7 C:G-+T:A transitions were G-+A changes in the sense strand. The pattern in the Austrian cohort was compared to the French, Icelandic, Norwegian and Scottish and our U.S. Caucasian groups and to a "European" profile consisting of the combined data for France, Scotland, Norway, and Iceland (Table II) . Pairwise group analyses of the eight classes of mutation among the groups (Fisher Exact Test; 2 x 8 table -see  Table II , footnotes) indicated an intergroup difference between the "Europeans" and the U.S. (P = 0.024) patients as well as a difference between the "Europeans" and the Austrians (P = 0.027). The major intergroup differences were due to a higher frequency of A:T--T:A transversions in the Austrians (P = 0.006) and an abundance of microdeletions in the U.S. whites (P = 0.012). The (25) and less than 10% of all mutations in the factor IX gene (26) . The pattern of mutation in the factor IX gene is similar across multiple ethnically and geographically diverse populations and is believed to reflect the endogenous (background) pattern of mutation in man (27) . Thus, the threefold excess of A:T-+T:A transversions in the Austrian group raises the possibility that there might be a factor contributing to mutagenesis that is more prevalent in that population. We are not aware of any epidemiological studies suggesting potential risk factors in the population of women residing in or near Graz/Austria. Xenobiotics which target primarily A:T base pairs can cause A:T-+T:A changes. For example, ethylene oxide, an industrial chemical produced in large volumes and also formed in vivo after metabolic conversion of ethene, causes A:T--T:A transversions in the hypoxanthine-guanine phosphoribosyltransferase gene (5 of 13 induced single base substitutions) (28) . Based on comparison of p53 mutations in breast cancers in different populations, we previously suggested that there are differences in factors contributing to breast carcinogenesis among racially and geographically diverse groups (11, 17, 18) . Coles We recently found a strong association between p53 mutation and shorter time to recurrence and a shorter survival in Table II breast cancers in U.S. Midwestern white women after adjustment for EBR, PR, and nodal status (17) . Several other groups have reported that p53 mutation, frequently assessed indirectly on the basis of immunohistochemical overexpression of p53 protein, is correlated with poor prognosis (reviewed in reference 4). However, in the present study there were only a few recurrences of breast cancer (8 of 60; 13.3%), none of the Austrian women died of their disease and neither the presence of a p53 mutation nor ER/PR status and lymph node status correlated with prognosis as assessed by disease free survival with a median follow-up of two years. The low recurrence and death rate in Austrians compared to the Midwestern U.S. group may be related to differences in the tumor stages between these two groups as assessed by comparison of all stages according to the American Joint Committee on Cancer (I, IIA, IIB, IIIA, IIIB, IV -Fisher Exact Test; 2 x 6 table; P = 0.028). Pairwise comparisons of the specific stages revealed, that the main difference between the Austrian and the U.S. Midwestern groups was a greater frequency of stage I tumors (23 of 60; 38.3%) in the Austrian cohort compared to the U.S. Caucasian women (6 of 53; 11.3%). The Caucasian population had many more stage II tumors, whereas the frequency of advanced stage III and IV breast cancers was nearly the same. In our U.S. sample with an 18-mo follow-up, 7 of 18 patients with p53 mutation died whereas none of the 35 patients without p53 mutation died. Longer follow-up and larger cohorts are necessary to assess the value of p53 mutation analysis as a prognostic indicator in stages I and II breast cancer in European and U.S. populations.
